04.09.2020 11:35:00

RhoVac appoints Professor Georg Hollaender to its Scientific Advisory Board

STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today September 4th 2020,  that it is continuing to strengthen the Scientific Advisory Board with a pediatric immunologist, by appointing Professor Georg Hollaender, Action Research Professor and Head of Department at Oxford University, UK  and Professor in Development Immunology, ETH Zurich, Switzerland, and Pediatric Immunology, University of Basel, Switzerland to the Scientific Advisory Board. Professor Hollaender is also Director of the Botnar Research Center for Child Health (BRCCH) in Basel, Switzerland.  

Professor Georg Hollaender, MD, PhD, joins RhoVac Scientific Advisory Board with an extensive experience in immunology, were his specific scientific focus concerns the molecular and cellular control of thymus development and function.  After his Medical Studies at Basel University, he proceeded his postdoctoral  research at Harvard Medical School, Boston, U.S. and held an Assistant Professor before returning to Switzerland. He was then appointed Full Professor in Molecular Medicine in Pediatrics 2003 at Basel University and held several academic positions there including Head of Research at the Basel University Childrens' Hospital. In 2010,  he was appointed as Action Research Professor of Paediatrics, University of Oxford, UK and in 2020 as full Professor in Developmental Immunology at Eidgenössische Technische Hochschule (ETH) in Zuerich, Switzerland.

CEO Anders Mansson comments: "We are excited and proud that Professor Hollaender, as a renowned expert in the field, wants to join our Scientific Advisory Board. With this recruitment, as well as the earlier ScientificAdvisory Board recruitments of prominent expertise, both pre-clinically and clinically, we now conclude that RhoVac has a scientific team in place that will enable us to stand toe to toe with the potential partners for RV001.

CONTACT:

For further information, please contact:
Anders Mansson - CEO, RhoVac AB
Phone number: +46 73-751 72 78
E-mail: info@rhovac.com

This information is such that RhoVac AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 4th September 2020.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/rhovac/r/rhovac-appoints-professor-georg-hollander-to-its-scientific-advisory-board,c3188987

The following files are available for download:

https://mb.cision.com/Main/13747/3188987/1302537.pdf

Release

SOURCE RhoVac

Nachrichten zu RhoVac ABmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu RhoVac ABmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

RhoVac AB 0,80 0,00% RhoVac AB